DMK Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
DMK Pharmaceuticals Stock Forecast and Price Target
The average target price set lately by experts for DMK Pharmaceuticals to reach by the end of the year is $0.03, which would imply a potential downside of approximately -40 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $0.03 and a low estimate of $0.02. If you're thinking of investing in DMK stock, it's critical to check out its competitors as well.
-40.00% Downside
DMK Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last zero years, DMK Pharmaceuticals's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $0.05 – an increase of 100.00%. The DMK Pharmaceuticals forecast is for Fair Value to reach $0.10 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$12.78 | Buy/Sell | $11.59 | 25.20% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£17.89 | Buy/Sell | £28.11 | 65.34% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$38.65 | Buy/Sell | $69.00 | 60.41% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$7.60 | Buy/Sell | $17.83 | 130.26% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$28.87 | Buy/Sell | $41.00 | 38.55% |
DMK Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, DMK Pharmaceuticals's Revenue has increased by 71.22%, going from $2.78M to $4.76M. 1 analysts predict DMK Pharmaceuticals's Revenue will decrease by 2.52% in the next year, reaching $4.64M. The DMK Pharmaceuticals forecast is for Revenue to reach $107.57M or grow by 2159.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$26.10 | Buy/Sell | $47.90 | 72.41% |
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$64.58 | Buy/Sell | $69.75 | 23.88% |
| COLL Stock Forecast | Collegium Pharmaceutical | Outperform |
11
|
$34.77 | Buy/Sell | $37.75 | 15.04% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | Buy/Sell | $10.00 | 16.46% |
| AQST Stock Forecast | Aquestive Therapeutics | Buy |
0
|
$4.50 | Buy/Sell | $6.33 | 100.00% |
| ZVRA Stock Forecast | Zevra Therapeutics | Buy |
10
|
$4.50 | Buy/Sell | $19.50 | 311.11% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EBS Stock Forecast | Emergent BioSolutions | Outperform |
16
|
$1.86 | Buy/Sell | $5.00 | 168.82% |
| DCTH Stock Forecast | Delcath Systems | Buy |
0
|
$4.70 | Buy/Sell | $19.25 | 336.17% |
| ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$0.75 | Buy/Sell | $3.50 | 300.00% |
DMK Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, DMK Pharmaceuticals's EBITDA has decreased from $-29.35M to $-23.58M – a 19.66% drop! The next year looks promising for DMK Pharmaceuticals, with analysts predicting EBITDA of $-27.95M – an increase of 18.54%. Over the next eight years, experts anticipate that DMK Pharmaceuticals's EBITDA will grow at a rate of 20.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRRX Stock Forecast | DURECT | Outperform |
9
|
$0.91 | Buy/Sell | $6.75 | 641.76% |
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.03 | Buy/Sell | $8.50 | -100.00% |
| ACRX Stock Forecast | AcelRx Pharmaceuticals | Buy |
6
|
$1.04 | Buy/Sell | $4.63 | 393.27% |
DMK Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, DMK Pharmaceuticals has seen a decline in its EBIT, from $-31.68M to $-25.06M – a 20.90% decrease. According to the 1 analysts polled, in the next year, DMK Pharmaceuticals's EBIT will fall by 44.01%, reaching $-14.03M. By 2030, professionals believe that DMK Pharmaceuticals's EBIT will have decreased by 235.75%, falling to $34.02M.
DMK Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last zero years, DMK Pharmaceuticals's EPS has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach $-0.96 – an increase of 100.00%. The DMK Pharmaceuticals forecast is for EPS to reach $1.23 or grow by 100.00%.
.jpg)